The availability of a new therapy is often the primary driver for diagnostic adoption. For Lynch syndrome, many at-risk individuals don't get tested because there's no preventative treatment. Newscom believes its therapy will create a strong incentive for genetic testing, mirroring how checkpoint inhibitors drove a 5x increase in MSI screening.

Roche's new sequencer, Alzheimer's test, and mass spectrometer aren't isolated projects. They form a cohesive strategy to provide tools across the entire patient journey—from risk assessment and screening to definitive diagnosis and recurrence monitoring.

The most important upcoming catalyst in neuroscience is Eli Lilly's TRAILBLAZER-ALZ 3 study, which aims to prevent Alzheimer's in at-risk patients. A positive result is expected to show a much larger effect size than seen in treating existing disease, potentially creating a massive new market and shifting the entire neurodegenerative paradigm.

Even with advanced imaging for diseases like Alzheimer's, adoption stalls if diagnostic results don't change patient management. Physicians won't use a test that answers an academic question but doesn't lead to an effective treatment, rendering the technology clinically irrelevant without answering the 'so what?' question.

In its Phase 2 trial, Acadia isn't using biomarkers to discover new insights but to confirm patients have the biological underpinnings of Alzheimer's disease. This marks a significant shift, demonstrating that biomarkers have matured into a standard diagnostic component for ensuring a homogenous and accurately defined patient population in clinical research.

The company's approach to Alzheimer's is a complete system, not just a drug. By leveraging Roche's diagnostic arm, they are pairing a new treatment with a simple, blood-based biomarker test for primary care physicians. This strategic pairing enables earlier patient identification, creating a more effective and accessible treatment paradigm.

The next era of CNS drug development will shift from single-target therapies for late-stage disease to early intervention. This involves using biomarkers to detect disease before symptoms appear and intervening with multimodal approaches that address multiple biological pathways simultaneously, such as amyloid, tau, and metabolic deficits in Alzheimer's.

The long-term vision for Alt-Pep's diagnostic extends beyond symptomatic patients or those with family histories. The goal is for it to become a routine screening assay, administered annually to the general population to catch the disease at its earliest molecular stages, changing the paradigm from treatment to prevention.

Roche’s new blood test is designed for primary care settings, not just specialists. It prioritizes high specificity to avoid false positives in a general population, aiming to cut the typical 3+ year diagnostic journey by enabling earlier, broader screening.